BOSTON, MA--(Marketwire - August 15, 2008) - Wolf, Greenfield & Sacks, P.C., a Boston intellectual property law firm, has announced that, on behalf of its client, Shire Pharmaceuticals, it has recently obtained an additional 1,126 days of patent term for ELAPRASE (idursulfase), a treatment for patients with Hunter Syndrome (Mucopolysaccharidosis II, MPS II). Hunter syndrome is a rare, life-threatening genetic condition that results from the absence or insufficient levels of the lysosomal enzyme iduronate-2-sulfatase. Without this enzyme, cellular waste products accumulate in tissues and organs, which then begin to malfunction.
